Results 21 to 30 of about 13,758 (226)

Hyperthermic intrathoracic/intraperitoneal chemotherapy versus conventional intrapleural/intraperitoneal chemotherapy for the malignant effusion: a multi-center randomized clinical trial

open access: yesInternational Journal of Hyperthermia, 2023
Objective To compare the efficacy and safety of hyperthermic intrathoracic/intraperitoneal chemotherapy versus conventional intrapleural/intraperitoneal chemotherapy in the treatment of malignant pleural or peritoneal effusion.Methods A randomized ...
Lili Liu   +14 more
doaj   +1 more source

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial PIPAC VEROne

open access: yesPleura and Peritoneum, 2022
Peritoneal carcinomatosis is the most frequent site of metastases in patients with gastric cancer. Current standard treatment is palliative systemic chemotherapy with very poor prognosis.
Casella Francesco   +10 more
doaj   +1 more source

Primary ovarian high-grade endometrial stromal sarcoma: a case report

open access: yesJournal of Medical Case Reports, 2021
Background Primary ovarian high-grade endometrial stromal sarcoma is a very rare disease. Even though it has poor prognosis, the gold standard treatment has not been established owing to its rarity.
Ji Sun Lee   +5 more
doaj   +1 more source

Cytoreduction and HIPEC in the treatment of "unconventional" secondary peritoneal carcinomatosis [PDF]

open access: yes, 2015
BACKGROUND: Peritoneal metastasis (PM) is considered a terminal and incurable disease. In the last 30 years, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) radically changed the therapeutic approach for these patients ...
Accarpio, Fabio   +8 more
core   +2 more sources

Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy indicated in hepatobiliary malignancies?

open access: yesWorld Journal of Surgical Oncology, 2020
Background Hepatopancreaticobiliary malignancies with peritoneal carcinomatosis exhibit poor survival with current therapies: hepatocellular carcinoma 11 months with sorafenib, and pancreaticobiliary 9–14 months with systemic chemotherapy.
Natasha Leigh   +6 more
doaj   +1 more source

Prognostic factors influencing infectious complications after cytoreductive surgery and HIPEC. Results from a tertiary referral center [PDF]

open access: yes, 2019
Background. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) showed promising results in selected patients. High morbidity restrains its wide application.
Carbonari, Ludovica   +8 more
core   +1 more source

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for patients with peritoneal metastases from endometrial cancer [PDF]

open access: yes, 2017
Background: More information is needed for selection of patients with peritoneal metastases from endometrial cancer (EC) to undergo cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC). Methods: This study analyzed clinical,
Biacchi, Daniele   +9 more
core   +1 more source

Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model [PDF]

open access: yes, 2015
Cytoreductive surgery combined with intraperitoneal chemotherapy (IPC) is currently the standard treatment for selected patients with peritoneal carcinomatosis of colorectal cancer.
Ceelen, Wim   +6 more
core   +4 more sources

Effect of Intraperitoneal Radium-Labelled Microparticles on Compartmentalized Inflammation After Cytoreductive Surgery and Hypertherm Intraperitoneal Chemotherapy

open access: yesTechnology in Cancer Research & Treatment, 2023
Despite extensive treatment with surgery and chemotherapy many patients with peritoneal metastases from colorectal cancer experience intraperitoneal disease relapse. The α-emitting 224 radium-labelled microparticle radionuclide therapeutic Radspherin® is
Ebbe Billmann Thorgersen MD, PhD   +6 more
doaj   +1 more source

Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer [PDF]

open access: yes, 2019
Patients with advanced ovarian cancer develop recurrence despite initial treatment response to standard treatment of surgery and intravenous/intraperitoneal (IP) chemotherapy, partly due to a limited peritoneal exposure time of chemotherapeutics ...
Ceelen, Wim   +7 more
core   +2 more sources

Home - About - Disclaimer - Privacy